Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease

 
February 10, 2009

Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.09 mm.

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.

Related News

Common Drug Can Limit Radiation Damage to Cancer Patient’s Heart, Lungs

May 21, 2013 — Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can...

Zoll Receives Japanese Approval to Market Intravascular Temperature Management Technology

May 21, 2013 — Zoll Medical Corporation has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to enter the Japanese market with its Intravascular Temperature...

Inpatients Who Have STEMI Heart Attacks More Likely to Die Than Outpatients

May 20, 2013 — If someone suffers a heart attack while walking down the street and is taken to the hospital quickly, his/her chances of survival are very good. But if someone has a heart attack...

View all

Related Articles

Common Drug Can Limit Radiation Damage to Cancer Patient’s Heart, Lungs

May 21, 2013 — Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can...

Endovascular Repair Of Ruptured Aneurysms Saves More Lives Than Surgery

May 20, 2013 — Patients with ruptured...

University of Maryland Medical Center Launches Genetic-Testing Program For Cardiac Stent Patients

May 17, 2013 — Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their...

View all